Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A8GM
|
||||
| Former ID |
DNCL003469
|
||||
| Drug Name |
Ublituximab
|
||||
| Synonyms |
TG-1101
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Chronic lymphocytic leukaemia [ICD10:C91] | Phase 2 | [1] | ||
| Company |
TG Therapeutics
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [2] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of TG THERAPEUTICS. | ||||
| REF 2 | The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr?m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.